Jazz Pharmaceuticals (NASDAQ:JAZZ) PT Set at $176.00 by Oppenheimer

Share on StockTwits

Oppenheimer set a $176.00 price objective on Jazz Pharmaceuticals (NASDAQ:JAZZ) in a research report sent to investors on Monday morning, Stock Target Advisor reports. The brokerage currently has a buy rating on the specialty pharmaceutical company’s stock.

Several other equities research analysts have also issued reports on the stock. Piper Jaffray Companies set a $202.00 target price on shares of Jazz Pharmaceuticals and gave the stock a buy rating in a research note on Tuesday, May 28th. Wells Fargo & Co reaffirmed a hold rating and issued a $68.00 price target (up from $65.00) on shares of Colgate-Palmolive in a research note on Monday, June 17th. HC Wainwright set a $12.00 price target on shares of IMV and gave the company a buy rating in a research note on Friday, May 10th. Mizuho set a $148.00 price target on shares of Jazz Pharmaceuticals and gave the company a hold rating in a research note on Wednesday, July 3rd. Finally, Cantor Fitzgerald reaffirmed a buy rating and issued a $185.00 price target on shares of Jazz Pharmaceuticals in a research note on Tuesday, March 26th. Two equities research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average target price of $179.41.

JAZZ stock opened at $138.23 on Monday. The stock’s 50-day moving average price is $134.65. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.01 and a current ratio of 3.15. Jazz Pharmaceuticals has a 52-week low of $113.52 and a 52-week high of $181.46. The stock has a market cap of $7.99 billion, a price-to-earnings ratio of 11.29, a P/E/G ratio of 1.18 and a beta of 1.15.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its earnings results on Tuesday, May 7th. The specialty pharmaceutical company reported $3.27 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.83 by $0.44. Jazz Pharmaceuticals had a net margin of 24.88% and a return on equity of 27.35%. The business had revenue of $508.19 million for the quarter, compared to analyst estimates of $466.55 million. During the same period in the prior year, the company posted $2.98 EPS. The company’s revenue for the quarter was up 14.3% on a year-over-year basis. On average, research analysts expect that Jazz Pharmaceuticals will post 13.24 EPS for the current year.

A number of hedge funds have recently added to or reduced their stakes in the business. Advisor Group Inc. raised its holdings in Jazz Pharmaceuticals by 3.3% in the 4th quarter. Advisor Group Inc. now owns 3,755 shares of the specialty pharmaceutical company’s stock valued at $465,000 after acquiring an additional 120 shares during the last quarter. Carroll Financial Associates Inc. raised its holdings in Jazz Pharmaceuticals by 166.7% in the 1st quarter. Carroll Financial Associates Inc. now owns 200 shares of the specialty pharmaceutical company’s stock valued at $28,000 after acquiring an additional 125 shares during the last quarter. Nomura Asset Management Co. Ltd. raised its holdings in Jazz Pharmaceuticals by 1.7% in the 1st quarter. Nomura Asset Management Co. Ltd. now owns 8,750 shares of the specialty pharmaceutical company’s stock valued at $1,251,000 after acquiring an additional 150 shares during the last quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Jazz Pharmaceuticals by 2.1% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 7,294 shares of the specialty pharmaceutical company’s stock valued at $1,043,000 after acquiring an additional 153 shares during the last quarter. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at about $25,000. Institutional investors own 89.77% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

See Also: How to calculate compound interest

Analyst Recommendations for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.